A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib (pd-0332991) In Healthy Volunteers To Estimate The Effect Of Antacid Treatment On The Bioavailability Of A 125 Mg Single Dose Of Six Experimental Formulations Of Palbociclib Relative To Palbociclib Administration Alone Under Fasted Conditions
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary) ; Rabeprazole
- Indications Acute myeloid leukaemia; Bone metastases; Brain metastases; Breast cancer; Cancer; Colorectal cancer; Gastrointestinal stromal tumours; Malignant melanoma; Mantle-cell lymphoma; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Feb 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 13 Dec 2014 New trial record